Leerink Partnrs Has Negative Outlook of DSGN Q2 Earnings

Design Therapeutics, Inc. (NASDAQ:DSGN) – Equities research analysts at Leerink Partnrs cut their Q2 2025 EPS estimates for Design Therapeutics in a report released on Wednesday, May 7th. Leerink Partnrs analyst J. Schwartz now anticipates that the company will earn ($0.33) per share for the quarter, down from their prior estimate of ($0.26). The consensus estimate for Design Therapeutics’ current full-year earnings is ($0.91) per share. Leerink Partnrs also issued estimates for Design Therapeutics’ Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.33) EPS, FY2025 earnings at ($1.30) EPS and FY2026 earnings at ($1.49) EPS.

Design Therapeutics Trading Down 1.4%

Shares of DSGN opened at $3.57 on Monday. The stock has a market capitalization of $202.67 million, a P/E ratio of -4.20 and a beta of 1.77. The firm’s fifty day simple moving average is $3.98 and its two-hundred day simple moving average is $4.93. Design Therapeutics has a 12 month low of $2.60 and a 12 month high of $7.77.

Design Therapeutics (NASDAQ:DSGN) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.03).

Institutional Trading of Design Therapeutics

A number of institutional investors have recently bought and sold shares of DSGN. Barclays PLC boosted its position in Design Therapeutics by 34.2% during the third quarter. Barclays PLC now owns 96,635 shares of the company’s stock valued at $520,000 after acquiring an additional 24,602 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Design Therapeutics by 186.9% during the third quarter. JPMorgan Chase & Co. now owns 40,687 shares of the company’s stock valued at $219,000 after acquiring an additional 26,503 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in Design Therapeutics during the fourth quarter valued at $74,000. Rhumbline Advisers boosted its position in shares of Design Therapeutics by 4.7% during the 4th quarter. Rhumbline Advisers now owns 52,932 shares of the company’s stock worth $327,000 after purchasing an additional 2,365 shares in the last quarter. Finally, Palumbo Wealth Management LLC boosted its position in shares of Design Therapeutics by 48.7% during the 4th quarter. Palumbo Wealth Management LLC now owns 54,696 shares of the company’s stock worth $337,000 after purchasing an additional 17,922 shares in the last quarter. Institutional investors own 56.64% of the company’s stock.

Design Therapeutics Company Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.